Tags

Type your tag names separated by a space and hit enter

CSF levels of heart fatty acid binding protein are altered during early phases of Alzheimer's disease.
J Alzheimers Dis 2010; 22(4):1281-8JA

Abstract

Heart fatty acid binding protein (HFABP) has been proposed as a putative marker for dementia disorders. To evaluate the value of this protein as an early marker of Alzheimer's disease (AD), we analyzed HFABP level and the classical biomarkers amyloid-β (Aβ)1-42, total tau (t-tau), and phosphorylated tau (p-tau) in cerebrospinal fluid (CSF) of patients with mild cognitive impairment (MCI) followed up for four years (n=41), AD (n=32), and subjects with other neurological diseases without dementia (OND, n=25). HFABP levels were higher in AD patients and in MCI converting to AD (MCI-AD) with respect to OND and to cognitively stable MCI patients (MCI-MCI). The receiver operator characteristics analysis for HFABP alone showed a sensitivity of 87% and a specificity of 81% for AD versus OND (area under the curve, AUC=0.83); sensitivity and specificity were 46% and 94%, respectively, when comparing MCI-MCI versus MCI-AD. CSF HFABP levels showed a strong positive correlation with both t-tau and p-tau. Interestingly, the ratio between HFABP and Aβ1-42 improved the performance in distinguishing AD from OND (sensitivity: 90%; specificity 82%, AUC=0.89), and gave the best accuracy in discriminating MCI-AD from MCI-MCI (sensitivity: 80%; specificity 100%, AUC=0.90). Survival analysis by means of Kaplan-Meier curve showed a significantly higher proportion of MCI patients converting to AD in the group with higher values of HFABP/Aβ1-42 ratio (cut-off=0.7). A significant correlation between HFABP/Aβ1-42 ratio and MMSE annual decrease rate was also documented (p<0.0001). HFABP /Aβ1-42 ratio might be a useful predictor of conversion in MCI patients.

Authors+Show Affiliations

Clinica Neurologica, Ospedale S. Maria della Misericordia, Università di Perugia, Perugia, Italy. parnetti@unipg.itNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

20930282

Citation

Chiasserini, Davide, et al. "CSF Levels of Heart Fatty Acid Binding Protein Are Altered During Early Phases of Alzheimer's Disease." Journal of Alzheimer's Disease : JAD, vol. 22, no. 4, 2010, pp. 1281-8.
Chiasserini D, Parnetti L, Andreasson U, et al. CSF levels of heart fatty acid binding protein are altered during early phases of Alzheimer's disease. J Alzheimers Dis. 2010;22(4):1281-8.
Chiasserini, D., Parnetti, L., Andreasson, U., Zetterberg, H., Giannandrea, D., Calabresi, P., & Blennow, K. (2010). CSF levels of heart fatty acid binding protein are altered during early phases of Alzheimer's disease. Journal of Alzheimer's Disease : JAD, 22(4), pp. 1281-8. doi:10.3233/JAD-2010-101293.
Chiasserini D, et al. CSF Levels of Heart Fatty Acid Binding Protein Are Altered During Early Phases of Alzheimer's Disease. J Alzheimers Dis. 2010;22(4):1281-8. PubMed PMID: 20930282.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - CSF levels of heart fatty acid binding protein are altered during early phases of Alzheimer's disease. AU - Chiasserini,Davide, AU - Parnetti,Lucilla, AU - Andreasson,Ulf, AU - Zetterberg,Henrik, AU - Giannandrea,David, AU - Calabresi,Paolo, AU - Blennow,Kaj, PY - 2010/10/9/entrez PY - 2010/10/12/pubmed PY - 2011/5/26/medline SP - 1281 EP - 8 JF - Journal of Alzheimer's disease : JAD JO - J. Alzheimers Dis. VL - 22 IS - 4 N2 - Heart fatty acid binding protein (HFABP) has been proposed as a putative marker for dementia disorders. To evaluate the value of this protein as an early marker of Alzheimer's disease (AD), we analyzed HFABP level and the classical biomarkers amyloid-β (Aβ)1-42, total tau (t-tau), and phosphorylated tau (p-tau) in cerebrospinal fluid (CSF) of patients with mild cognitive impairment (MCI) followed up for four years (n=41), AD (n=32), and subjects with other neurological diseases without dementia (OND, n=25). HFABP levels were higher in AD patients and in MCI converting to AD (MCI-AD) with respect to OND and to cognitively stable MCI patients (MCI-MCI). The receiver operator characteristics analysis for HFABP alone showed a sensitivity of 87% and a specificity of 81% for AD versus OND (area under the curve, AUC=0.83); sensitivity and specificity were 46% and 94%, respectively, when comparing MCI-MCI versus MCI-AD. CSF HFABP levels showed a strong positive correlation with both t-tau and p-tau. Interestingly, the ratio between HFABP and Aβ1-42 improved the performance in distinguishing AD from OND (sensitivity: 90%; specificity 82%, AUC=0.89), and gave the best accuracy in discriminating MCI-AD from MCI-MCI (sensitivity: 80%; specificity 100%, AUC=0.90). Survival analysis by means of Kaplan-Meier curve showed a significantly higher proportion of MCI patients converting to AD in the group with higher values of HFABP/Aβ1-42 ratio (cut-off=0.7). A significant correlation between HFABP/Aβ1-42 ratio and MMSE annual decrease rate was also documented (p<0.0001). HFABP /Aβ1-42 ratio might be a useful predictor of conversion in MCI patients. SN - 1875-8908 UR - https://www.unboundmedicine.com/medline/citation/20930282/CSF_levels_of_heart_fatty_acid_binding_protein_are_altered_during_early_phases_of_Alzheimer's_disease_ L2 - https://content.iospress.com/openurl?genre=article&amp;id=doi:10.3233/JAD-2010-101293 DB - PRIME DP - Unbound Medicine ER -